Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting By: IN8bio, Inc via GlobeNewswire April 24, 2024 at 08:00 AM EDT NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression Session Type: In-Person Oral Presentation Session Title: Novel Production Platforms Abstract Number: 282 Location: Ballroom 2 Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes. About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com. Corporate Contact:IN8bio, Inc.Glenn Schulman, PharmD, MPH203.494.7411gdschulman@IN8bio.com InvestorsMeru AdvisorsLee M. Sternlstern@meruadvisors.com Media ContactKimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting By: IN8bio, Inc via GlobeNewswire April 24, 2024 at 08:00 AM EDT NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression Session Type: In-Person Oral Presentation Session Title: Novel Production Platforms Abstract Number: 282 Location: Ballroom 2 Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes. About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com. Corporate Contact:IN8bio, Inc.Glenn Schulman, PharmD, MPH203.494.7411gdschulman@IN8bio.com InvestorsMeru AdvisorsLee M. Sternlstern@meruadvisors.com Media ContactKimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.com
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression Session Type: In-Person Oral Presentation Session Title: Novel Production Platforms Abstract Number: 282 Location: Ballroom 2 Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes. About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com. Corporate Contact:IN8bio, Inc.Glenn Schulman, PharmD, MPH203.494.7411gdschulman@IN8bio.com InvestorsMeru AdvisorsLee M. Sternlstern@meruadvisors.com Media ContactKimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.com